ReviewAnnual review of pharmacology and toxicology2016
Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders.
Review in Annual review of pharmacology and toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Amine-responsive Rhodopsin-like GPCRs in ocular pathology: mechanistic associations, candidate biomarkers, and therapeutic potential.Frontiers in physiology · 2026Review
- Cyclic nucleotide signaling as a drug target in retinitis pigmentosa.FEBS letters · 2025Review
- Effects of taurine, brimonidine and betaxolol on oscillation modulation and stimulation efficiency in degenerated rd10 mouse retinas.Scientific reports · 2025Article
- α1D Adrenergic Receptor Antagonism Protects Against High Glucose-Induced Mitochondrial Dysfunction and Blood Retinal Barrier Breakdown in ARPE-19 Cells.International journal of molecular sciences · 2025Article
- Retinal Proteome Profiling of Inherited Retinal Degeneration Across Three Different Mouse Models Suggests Common Drug Targets in Retinitis Pigmentosa.Molecular & cellular proteomics : MCP · 2024Article
- A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models.Nature communications · 2024Article
- The Role of Reversible Phosphorylation ofInternational journal of molecular sciences · 2022Review
- New Approach for Untangling the Role of Uncommon Calcium-Binding Proteins in the Central Nervous System.Brain sciences · 2021Review
- 17β-Estradiol Delivered in Eye Drops: Evidence of Impact on Protein Networks and Associated Biological Processes in the Rat Retina through Quantitative Proteomics.Pharmaceutics · 2020Article
- Montelukast Prevents Early Diabetic Retinopathy in Mice.Diabetes · 2019Article
- A Mixture of U.S. Food and Drug Administration-Approved Monoaminergic Drugs Protects the Retina From Light Damage in Diverse Models of Night Blindness.Investigative ophthalmology & visual science · 2019Article
- Modulation of α-adrenoceptor signalling protects photoreceptors after retinal detachment by inhibiting oxidative stress and inflammation.British journal of pharmacology · 2019Article
- Monomethyl Fumarate Protects the Retina From Light-Induced Retinopathy.Investigative ophthalmology & visual science · 2019Article
- Human aging and disease: Lessons from age-related macular degeneration.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- A Combination of G Protein-Coupled Receptor Modulators Protects Photoreceptors from Degeneration.The Journal of pharmacology and experimental therapeutics · 2018Article
- The Role of ERK1/2 Activation in Sarpogrelate-Mediated Neuroprotection.Investigative ophthalmology & visual science · 2018Article
- Article
- Transcriptome profiling of NIH3T3 cell lines expressing opsin and the P23H opsin mutant identifies candidate drugs for the treatment of retinitis pigmentosa.Pharmacological research · 2017Article
- Eyes on systems pharmacology.Pharmacological research · 2016Article
- Next generation sequencing technology and genomewide data analysis: Perspectives for retinal research.Progress in retinal and eye research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
In most biological systems, second messengers and their key regulatory and effector proteins form links between multiple cellular signaling pathways. Such signaling nodes can integrate the deleterious effects of genetic aberrations, environmental stressors, or both in complex diseases, leading to cell death by various mechanisms. Here we present a systems (network) pharmacology approach that, together with transcriptomics analyses, was used to identify different G protein-coupled receptors that experimentally protected against cellular stress and death caused by linked signaling mechanisms. We describe the application of this concept to degenerative and diabetic retinopathies in appropriate mouse models as an example. Systems pharmacology also provides an attractive framework for devising strategies to combat complex diseases by using (repurposing) US Food and Drug Administration-approved pharmacological agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.